Location: United States
Total raised: $15.2M
Funding Rounds 2
| Date | Series | Amount | Investors |
| 10.03.2026 | - | $5M | - |
| 25.11.2025 | Series A | $10.2M | - |
Mentions in press and media 6
| Date | Title | Description |
| 11.03.2026 | Alzheimer's Immune Breakthrough: MindImmune Secures $5M Funding | MindImmune received a significant $5 million award. The Alzheimer's Drug Discovery Foundation (ADDF) made this strategic investment. The funding accelerates MITI-101. This lead therapeutic candidate targets immune pathways. It aims to comba... |
| 10.03.2026 | MindImmune Receives $5M Investment | MindImmune, a Cambridge, MA-based biotechnology company, received a $5M investment. Alzheimer’s Drug Discovery Foundation made the investment. The company intends to use the funds to support completion of critical translational studies and ... |
| 10.03.2026 | MindImmune: $5 Million Award To Advance Immune-Driven Alzheimer’s Therapy | MindImmune, a biotechnology company focused on immune-based treatments for neurodegenerative diseases, announced it has secured a $5 million strategic award from the Alzheimer’s Drug Discovery Foundation (ADDF) to accelerate development of ... |
| 25.11.2025 | MindImmune Therapeutics Closes $10.2M Series A Extension; Brings Round Total to $30M | MindImmune Therapeutics, a Cambridge, MA-based developer of new treatments targeting the inflammatory drivers of neurodegenerative disease, closed a $10.2m Series A extension, which brought the total Series A capital raised to $30m. The fin... |
| 23.01.2018 | Incyte tries to fend off TRC's mini-tender offer to investors; Gritstone Oncology scoops Actelion CFO Jean-Marc Bellemin | → Incyte $INCY is counting on its investors to protect 0.71% — or 1,500,000 shares — of its common stock, from Canada’s TRC Capital, which is out to buy them at a discount price. The investment firm promised $88.88 per share in ... |
| - | MindImmune Therapeutics | “Breaking through barriers to new therapeutics for brain disease.” |